Evidence map›Paper›PMID 33405205›Full record

Observational studyJournal of neurovirology2021

Predictive factors of human cytomegalovirus reactivation in newly diagnosed glioblastoma patients treated with chemoradiotherapy.

R Ursu, J Doridam, E Chaugne, H Zannou, C Belin, S Cuzzubbo, L Sirven-Villaros, S Brichler, C Levy-Piedbois, A F Carpentier

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of neurovirology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Does human cytomegalovirus provide a novel therapeutic target for patients with glioblastoma?Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

R UrsuService de Neurologie, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris, France. renata.ursu@aphp.fr.ORCID 0000-0003-0123-8937
J DoridamAssistance Publique-Hôpitaux de Paris (AP-HP), Service de Neurologie, Hôpital Avicenne, 93009, Bobigny, France.
E ChaugneAssistance Publique-Hôpitaux de Paris (AP-HP), Service de Neurologie, Hôpital Avicenne, 93009, Bobigny, France.
H ZannouAssistance Publique-Hôpitaux de Paris (AP-HP), Service de Neurologie, Hôpital Avicenne, 93009, Bobigny, France.
C BelinService de Neurologie, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris, France.
S CuzzubboService de Neurologie, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris, France.
L Sirven-VillarosService de Neurologie, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris, France.
S BrichlerUFR de Santé, Médecine et Biologie Humaine, Université Paris 13, 93009, Bobigny, France.
C Levy-PiedboisInstitut de Radiothérapie des Hautes Energies (IRHE), 93009, Bobigny, France.
A F CarpentierService de Neurologie, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris, France.
Université Paris Cité · FRAssistance Publique – Hôpitaux de Paris · FRInserm · FRUniversité Sorbonne Paris Nord · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The human cytomegalovirus (HCMV) is a ubiquitous herpes virus which infects 40 to 99% of the population. HCMV reactivation may occur in the context of immunosuppression and can induce significant morbidities. Several cases of HCMV infections or HCMV reactivation have thus been reported in glioblastoma (GBM) patients treated with radio(chemo)therapy. With the aim to identify the main risk factors associated with HCMV reactivation, we reviewed all patients treated for a newly diagnosed GBM in our institution from October 2013 to December 2015. Age, sex, Karnofsky performance status (KPS), absolute lymphocyte count (ALC), serological HCMV status, and steroid doses were recorded at the start and 1 month after the end of radiotherapy (RT). Within the 103 patients analyzed, 34 patients (33%) had an initial negative serology for HCMV, and none of them developed a seroconversion after treatment. Among patients with positive HCMV IgG (n = 69), 16 patients (23%) developed a viremia at one point during treatment. Age (> 60 years), steroid intake, and ALC (< 1500/mm

Indexed as

Immunocompromised HostAdultAgedAged, 80 and overBrain NeoplasmsChemoradiotherapyCytomegalovirusCytomegalovirus InfectionsFemaleGlioblastomaHumansLatent InfectionMaleMiddle AgedRisk FactorsVirus ActivationChemoradiotherapyCytomegalovirusGlioblastomaReactivation

Identifiers

PMID33405205
OpenAlexW3120603752

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.